The FDA has awarded 11 grants equating to about $25 million of funding to clinical trials for the development of rare disease treatments.
List view / Grid view
Tuberous sclerosis complex (TSC)
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).